AR035482A1 - Uso de un compuesto de cianoquinolina para la manufactura de un medicamento para tratar o inhibir polipos colonicos - Google Patents

Uso de un compuesto de cianoquinolina para la manufactura de un medicamento para tratar o inhibir polipos colonicos

Info

Publication number
AR035482A1
AR035482A1 ARP010101143A ARP010101143A AR035482A1 AR 035482 A1 AR035482 A1 AR 035482A1 AR P010101143 A ARP010101143 A AR P010101143A AR P010101143 A ARP010101143 A AR P010101143A AR 035482 A1 AR035482 A1 AR 035482A1
Authority
AR
Argentina
Prior art keywords
manufacture
polyps
treat
medicinal product
cyanoquinoline compound
Prior art date
Application number
ARP010101143A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR035482A1 publication Critical patent/AR035482A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Quinoline Compounds (AREA)

Abstract

Uso de un compuesto de cianoquinolina para la manufactura de un medicamento para tratar o inhibir los pólipos colónicos que comprende proveer un compuesto de la fórmula 1 donde R1, R2, R3, R4, X, Y y n son como se definen en la memoria descriptiva, o su sal farmacéuticamente aceptable.
ARP010101143A 2000-03-13 2001-03-12 Uso de un compuesto de cianoquinolina para la manufactura de un medicamento para tratar o inhibir polipos colonicos AR035482A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52419600A 2000-03-13 2000-03-13

Publications (1)

Publication Number Publication Date
AR035482A1 true AR035482A1 (es) 2004-06-02

Family

ID=24088181

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010101143A AR035482A1 (es) 2000-03-13 2001-03-12 Uso de un compuesto de cianoquinolina para la manufactura de un medicamento para tratar o inhibir polipos colonicos

Country Status (23)

Country Link
EP (1) EP1263503B1 (es)
JP (1) JP2003526686A (es)
KR (2) KR20080009294A (es)
CN (1) CN1190197C (es)
AR (1) AR035482A1 (es)
AT (1) ATE308364T1 (es)
AU (2) AU2001245452B2 (es)
BR (1) BR0109165A (es)
CA (1) CA2402742C (es)
DE (1) DE60114580T2 (es)
DK (1) DK1263503T3 (es)
EA (1) EA200200976A1 (es)
ES (1) ES2248302T3 (es)
HK (1) HK1048775B (es)
HU (1) HUP0300547A2 (es)
IL (2) IL151249A0 (es)
MX (1) MXPA02008836A (es)
NO (1) NO20024356L (es)
NZ (1) NZ521117A (es)
PL (1) PL202873B1 (es)
TW (1) TWI262805B (es)
WO (1) WO2001068186A2 (es)
ZA (1) ZA200208178B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US7084156B2 (en) 2001-11-27 2006-08-01 Merck & Co., Inc. 2-Aminoquinoline compounds
JP4389204B2 (ja) * 2002-01-28 2009-12-24 宇部興産株式会社 キナゾリン−４−オン誘導体の製造方法
CN1330627C (zh) 2002-02-05 2007-08-08 惠氏公司 N－酰基－2－氨基－4－烷氧基－5－硝基苯甲酸类化合物的合成方法
CN1304374C (zh) * 2002-04-30 2007-03-14 永进药品工业株式会社 可用做caspase－3抑制剂的喹啉衍生物及其制备方法和药用组合物
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
CA2529611C (en) 2002-12-20 2009-12-15 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
SI2213661T1 (sl) 2003-09-26 2011-11-30 Exelixis Inc c-Met modulatorji in postopki uporabe
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
BRPI0511132A (pt) 2004-05-14 2007-11-27 Pfizer Prod Inc derivados de pirimidina e composição farmacêutica compreendendo os mesmos
WO2005111022A1 (en) 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidines derivatives for the treatment of abnormal cell growth
JP2007537238A (ja) 2004-05-14 2007-12-20 ファイザー・プロダクツ・インク 異常細胞増殖の治療のためのピリミジン誘導体
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
BRPI0610142A2 (pt) * 2005-05-25 2011-01-04 Wyeth Corp método para preparar um composto da fórmula (i) ; e método para preparar um ácido da fórmula (vii)
US8404697B2 (en) 2005-11-11 2013-03-26 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
DE102006029446A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Neue 3-substituierte-Chinoline als Kinase-Inhibitoren
DE102006029445A1 (de) * 2006-06-21 2007-12-27 Bayer Schering Pharma Ag Neue 3-Cyano-chinoline als Kinase-Inhibitoren
PT2068880E (pt) 2006-09-18 2012-07-12 Boehringer Ingelheim Int Método para tratamento do cancro apresentando mutações no egfr
DE102007024470A1 (de) 2007-05-24 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Neue Sulfoximin-substituierte Chinolin- bzw. Chinazolinderivate als Kinase-Inhibitoren
EP2072502A1 (de) 2007-12-20 2009-06-24 Bayer Schering Pharma Aktiengesellschaft Sulfoximid-substituierte Chinolin- und Chinazolinderivate als Kinase-Inhibitoren
US8877776B2 (en) 2009-01-16 2014-11-04 Exelixis, Inc. (L)-malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
CN102625799A (zh) 2009-06-25 2012-08-01 安姆根有限公司 杂环化合物及其用途
ES2731901T3 (es) 2009-07-06 2019-11-19 Boehringer Ingelheim Int Proceso para el secado de BIBW2992, de sus sales y de formulaciones farmacéuticas sólidas que comprenden este ingrediente activo
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CA2816957A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
JP6533997B2 (ja) * 2014-12-26 2019-06-26 株式会社ヤクルト本社 Ｚｎｆ１４３阻害活性を有する化合物およびその利用
US10246424B2 (en) * 2015-04-10 2019-04-02 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356339A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
CA3005089A1 (en) 2015-11-16 2017-05-26 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
US11059819B2 (en) 2017-01-26 2021-07-13 Janssen Biotech, Inc. Fused hetero-hetero bicyclic compounds and methods of use thereof
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
EP3573964A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Benzothiophene and benzothiazole compounds and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
MX2019013954A (es) 2017-05-25 2020-08-31 Araxes Pharma Llc Inhibidores covalentes de kras.
US11639346B2 (en) 2017-05-25 2023-05-02 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS
US10736897B2 (en) 2017-05-25 2020-08-11 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) * 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
DE60031127T2 (de) * 1999-08-12 2007-02-01 Wyeth Holdings Corp. Nsaid und egfr kinase inhibitoren enthaltende pharmazeutische formulierung zur behandlung oder inhibierung von dickdarmpolypen und kolorektalem krebs

Also Published As

Publication number Publication date
ZA200208178B (en) 2004-02-11
NO20024356L (no) 2002-11-12
HK1048775B (zh) 2006-01-20
ES2248302T3 (es) 2006-03-16
EP1263503A2 (en) 2002-12-11
BR0109165A (pt) 2003-04-22
CA2402742C (en) 2009-05-12
IL151249A (en) 2008-06-05
CA2402742A1 (en) 2001-09-20
KR20080009294A (ko) 2008-01-28
KR20020092987A (ko) 2002-12-12
AU2001245452B2 (en) 2005-05-05
TWI262805B (en) 2006-10-01
MXPA02008836A (es) 2003-02-10
NZ521117A (en) 2005-02-25
KR100817423B1 (ko) 2008-03-27
NO20024356D0 (no) 2002-09-12
CN1190197C (zh) 2005-02-23
HK1048775A1 (en) 2003-04-17
EP1263503B1 (en) 2005-11-02
AU4545201A (en) 2001-09-24
PL363072A1 (en) 2004-11-15
WO2001068186A2 (en) 2001-09-20
DE60114580T2 (de) 2006-07-27
EA200200976A1 (ru) 2003-02-27
HUP0300547A2 (hu) 2003-07-28
WO2001068186A3 (en) 2002-01-17
PL202873B1 (pl) 2009-07-31
JP2003526686A (ja) 2003-09-09
ATE308364T1 (de) 2005-11-15
CN1429126A (zh) 2003-07-09
IL151249A0 (en) 2003-04-10
DE60114580D1 (de) 2005-12-08
DK1263503T3 (da) 2006-02-13

Similar Documents

Publication Publication Date Title
AR035482A1 (es) Uso de un compuesto de cianoquinolina para la manufactura de un medicamento para tratar o inhibir polipos colonicos
UY26635A1 (es) Métodos sinérgicos y composiciones para el tratamiento del cáncer
CY1108070T1 (el) Παραγωγα κινολινονης, ως αναστολεις κινασης τυροσινης
ECSP066312A (es) Derivados piridilo y su uso como agentes terapéuticos
PA8591701A1 (es) Derivados de pirrolopirimidina
PE20020521A1 (es) Compuestos heterociclicos sustituidos para tratar la resistencia a multiples drogas
TNSN06032A1 (en) Pyridazine derivatives and their use as therapeutic agents
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
NO20060973L (no) Pyridylderivater og deres anvendelse som tempeutiske midler
GEP20053688B (en) Substituted-Triazolopyrimidines as Anticancer Agents
PA8514401A1 (es) Nuevos derivados de piperazina
ECSP066313A (es) Derivados de la piridazina y su uso como agentes terapéuticos
ATE452129T1 (de) N-phenyl-2-pyrimidine-amine derivatives
EA200300081A1 (ru) Гидрогель-управляемая лекарственная форма
CY1109037T1 (el) Πιπεραζινες χρησιμες για θεραπεια πονου
GEP20094675B (en) Heteroaryl- tetra-hydropiperidyl compounds useful for treating or preventing pain
AR027355A1 (es) Acidos tiazolidincarboxilicos
SE9900961D0 (sv) Novel compounds
ES2180933T3 (es) Inhibidor de la serina-proteasa.
BR0115936A (pt) 2-anilino-benzimidazóis substituìdos e sua aplicação como inibidores de nhe
CO5200778A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de b enzimidazol, administrada para prevenir y tratar el cancer e inhibir la metastasis
TR200200263T2 (tr) Yeni seçiçi retinoid agonistleri
BR0209645A (pt) Oxazolo- e furopirimidinas e seu uso como medicamentos
AR007021A1 (es) Derivados de 3-descladinosa-2,3-anhidroeritromicina, procedimientos para su preparacion, compuestos para su exclusivo uso en dichos procedimientosy procedimiento para su preparacion, una composicion farmaceutica para tratar infecciones bacterianas y el uso de estos compuestos para preparar medicamentos
SE0003476D0 (sv) Compounds

Legal Events

Date Code Title Description
FC Refusal
FB Suspension of granting procedure